News Feed

Mumbai, India; June 06, 2018: Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for HAILEY^TM 1.5/30 (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1.5 mg/30 mcg), the generic version of Loestrin^®1 21 1.5/30 Tablets, of Allergan Pharmaceuticals International Limited (Allergan) and for HAILEY^TM Fe 1.5/30 (Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets, 1.5 mg/30 mcg), the generic version of Loestrin^® Fe 1.5/30, also of Allergan. According to IQVIA^TM sales data for the 12 month period ending April 2018, the Loestrin^® 21 1.5/30 Tablets market² achieved annual sales of approximately $24.2 million* and the Loestrin^® Fe 1.5/30 market achieved annual sales of approximately $41.3 million. Glenmark’s current portfolio consists of 137 products authorized for distribution in the U.S. marketplace and 61 ANDAs pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. ¹All brand names and trademarks are the property of their respective owners. ²Market includes brand and all available therapeutic equivalents *IQVIATM National Sales Perspectives: Retail & Non-Retail, April 2018

Mumbai, India; June 06, 2018: Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for HAILEY^TM 1.5/30 (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1.5 mg/30 mcg), the generic version of Loestrin^®1 21 1.5/30 Tablets, of Allergan Pharmaceuticals International Limited (Allergan) and for HAILEY^TM Fe 1.5/30 (Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets, 1.5 mg/30 mcg), the generic version of Loestrin^® Fe 1.5/30, also of Allergan. According to IQVIA^TM sales data for the 12 month period ending April 2018, the Loestrin^® 21 1.5/30 Tablets market² achieved annual sales of approximately $24.2 million* and the Loestrin^® Fe 1.5/30 market achieved annual sales of approximately $41.3 million. Glenmark’s current portfolio consists of 137 products authorized for distribution in the U.S. marketplace and 61 ANDAs pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. ¹All brand names and trademarks are the property of their respective owners. ²Market includes brand and all available therapeutic equivalents *IQVIATM National Sales Perspectives: Retail & Non-Retail, April 2018